Targeting the leptin-STAT3-FAO axis might potentiate robust anti-tumor CD8 + T immune killing effect, in addition to inhibiting cancer stem cells (CSCs) and chemo-resistant tumor cells in breast cancer. Here, CD8A is linked to neoplasm.